Background: This retrospective study aims to assess the usefulness of SUV max from FDG-PET imaging as a prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT. Methods: This study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage IA/IB NSCLC. All patients were treated with 60Gy in 3 fractions with a median treatment time of six days. Local, regional, and distant failures were evaluated independently according to the terms of RTOG1021. Local, regional, and distant control, overall-and progression-free survival were estimated by the Kaplan-Meier method. Cox proportional hazards regression was performed to determine whether SUV max , age, KPS, gender, tumor size/T stage, or smoking history influenced outcomes. SUV max was evaluated as both a continuous and as a dichotomous variable using a cutoff of <5 and ≥5.
Introduction
[ 18 F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) is an important tool in the initial staging and subsequent assessment of patients diagnosed and treated for non-small cell lung cancer (NSCLC) [1, 2] . FDG-PET imaging relies on the functional properties that define malignancies including increased glucose metabolism. This uptake is linked to tumor proliferation and metastatic potential and recent investigations demonstrate the usefulness of PET imaging as a prognosticator for eventual outcomes.
The International Association for the Study of Lung Cancer (IASLC) reviewed 21 studies that assessed the utility of the maximum standardized uptake value (SUV max ) in NSCLC and determined that tumors with higher SUV max have poorer prognoses [3] . Other recent studies have attempted to determine the utility of SUV max under a more narrow scope including that of early-stage NSCLC treated with stereotactic body radiation therapy (SBRT), an emerging technique typically reserved for patients who are medically-inoperable or who refuse surgery [4, 5] . Multiple studies demonstrate that pretreatment SUV max predicts for clinical outcomes in patients with early-stage NSCLC treated with SBRT [6] [7] [8] . To the contrary, studies from Cleveland Clinic and Indiana University failed to find a correlation between pre-treatment SUV max and survival [9, 10] . As early-stage NSCLC is a potentially curable disease with SBRT, here, an SUV max cutoff that predicts for more aggressive disease in patients with solitary, peripheral, primary stage I NSCLC is identified.
Methods and materials

Patients and workup
This study includes 95 non-consecutive patients treated for biopsy-confirmed peripheral stage IA/IB between October 2005 and May 2011 [11] . This research was determined to have exemption status by our Institutional Review Board. All patients were staged according to the 7 th edition of the AJCC criteria. No tumor was located within 2 cm of the proximal bronchial tree and no patient was previously treated for lung cancer. All patients had a pre-SBRT FDG-PET-CT scan with a documented SUV max . Of these patients, 14 were operable candidates but refused surgical therapy, while the remaining 81 patients had significant pulmonary or cardiac comorbidity that precluded definitive surgical management ( Table 1) . As a part of the staging, all patients underwent a PET-CT scan. The SUV max was obtained from review of the formally dictated radiology report.
Simulation and treatment
Each patient was positioned supine with arms raised above the head for the CT simulation. A thin-slice 4-D high resolution CT (2.5 mm) and 1.25 mm helical CT with intravenous contrast was obtained while the patient was immobilized in a custom BodyFIX vacuum bag (Electa). For patients treated with CyberKnife™, Synchrony Respiratory Tracking System (Accuray, Inc, Sunnyvale, CA) was utilized in conjunction with the 4D-CT to ensure fiducial movement in sync with the GTV. For Trilogy™ and Trubeam™ patients, image-guided respiratory cycle motion was accounted for via Varian Real-Time Position Management System (Varian Medical Systems, Palo Alto, CA). Respiratory gating was incorporated for patients with tumor motion > 0.5 cm. The acquired images were then transferred to the treatment planning workstation using either Accuray MulitPLAN™ (Accuray, Inc, Sunnyvale, CA) or Varian Eclipse™ (Varian Medical Systems, Palo Alto, CA). The AAA planning algorithm was utilized for patients treated on Trilogy™ and Trubeam™ and the pencil beam algorithm for patients treated on CyberKnife™. The tumor volume and any surrounding critical structures, including the spinal cord, heart, esophagus, brachial plexus and normal lung, were manually delineated by a radiosurgical team consisting of a radiation oncologist, a medical physicist, and a thoracic surgeon. The gross tumor volume (GTV) was defined as the tumor alone. To account for setup error and residual motion detected on end-exhalation 4D-CT, a minimum expansion of 5 mm margin was added to create the planning target volume (PTV). An additional margin based on motion assessment was added to create an internal target volume (ITV) to be used with gating. Dose-volume histograms were calculated for the target volume and nearby critical structures to select the optimal treatment plan, which provided at least 95% of the prescription dose to the PTV while sparing surrounding organs-atrisk. If surrounding organs-at-risk were deemed to be at excess risk for toxicity, a plan with lower PTV coverage was accepted.
SBRT was performed using CyberKnife™ Robotic Radiosurgery System (Accuray, Inc, Sunnyvale, CA for 39 patients, Trilogy™ Radiosurgery System (Varian Medical Systems, Palo Alto, CA) for 54 patients and Trubeam™ Radiosurgery System (Varian Medical Systems, Palo Alto, CA) for 2 patients. All lesions were treated with heterogeneity correction to 60 Gy in 3 fractions every other day with a median of 6 elapsed days from beginning of treatment to end (range 3-21 days). For patients treated on the Trilogy™ and Trubeam ™ platforms, conebeam CT (CBCT) was performed daily to separate setup error from tumor reposition error. The treating physician checked and modified the alignment based on target relocalization in the fused imaging.
Disease assessment and clinical follow-Up
After treatment, patients were scheduled to have either a CT or PET/CT scan every 3 months with a clinical evaluation. Response to treatment was evaluated by the RECIST v1.1 criteria and documented as a complete response, partial response (greater than 30% decrease in the longest [12] . Follow-up imaging was reevaluated to classify local, regional, and distant failures similar to the definitions of RTOG 1021 [13] . Local failures were defined as recurrence within the originally involved lobe or within 2 cm of the initial primary but located outside the originally involved lobe. Regional failure included non-involved ipsilateral lobes, as well as ipsilateral hilar, mediastinal, and subcarinal lymph nodes. Distant failures enveloped ipsilateral supraclavicular and contralateral lymph nodes and all other distant sites. Progression-free survival was defined as the time to a specified recurrence and was measured from the last day of treatment to that event. Death was not included as an endpoint for PFS. Local, regional, and distant control, overall-and progression-free survival were estimated by the Kaplan-Meier method. The ANOVA test was utilized to determine correlations between SUV max , tumor histology, and stage. Forward conditional Cox proportional hazards regression was performed to determine whether SUV max (continuous/dichotomous), age (continuous), KPS (continuous), gender, tumor T stage, tumor histology, or smoking pack years (continuous) influenced outcomes. SUV max was evaluated in univariate and multivariate analyses as both a continuous and as a dichotomous variable using a cutoff of <5 and ≥5 as described in previous reports [6, 9, 14, 15] . All statistics were completed using SPSS version 20 (IBM Corp, Armonk, NY). Significance was set at p ≤ 0.05. 
Results
Toxicity
In the 95 patients treated with SBRT, three acute Grade 3 toxicities were observed. The Grade 3 toxicities were comprised of radiation pneumonitis, pneumonia, and pleural effusion. Additionally, there was one Grade 2 dyspnea and two Grade 2 chest pains. Late toxicities included one Grade 3 dyspnea and one Grade 2 dyspnea.
Clinical outcomes
Median overall survival (OS) and progression-free survival (PFS) were 25.3 and 40.3 months, respectively. The 2-year actuarial rates of events following treatment are shown in Table 3 . Two-year overall and cause-specific survivals were 64.2% and 94.5%, respectively. Overall PFS at two years was 93.7%. Two-year local control was Table 4) . On ANOVA test, tumor Tstage and histology were both significantly correlated to SUV max (p = .046 and p = .013, respectively).
In multivariate analysis, SUV max did not predict for OS as a dichotomous or continuous variable and only KPS and T-stage remained significant (p < .0001 and p = .013, respectively). It did, however, predict for PFS as a continuous variable (p = .008, HR = 1.111), though not as a dichotomous variable (Table 4) . SUV max also trended toward significance for LC and DC as a continuous variable (p = .057 and p = .092, respectively).
Discussion
Previous reports indicate that tumor aggressiveness defined by an increased Ki-67 is correlated with SUV max and tumor differentiation but not with TNM stage [16, 17] . Lung tumors with high Ki-67 are associated with decreased survival [18] as well as shortened progression-free survival in surgical series [19, 20] . This would indicate that tumors with higher SUV max values have an increased likelihood of having a more aggressive biology regardless of size which in our study, manifests in decreased progression-free survival.
Our study of patients with primary, peripheral, biopsyproven, stage I NSCLC treated with a homogenous SBRT Figure 1 Overall and progression-free survivals as differentiated by SUV max . A: Overall survival differences between SUV max categories, p= 0.024; B: Progression-free survival differences between SUV max categories, p= 0.024. Comparison of SUV max categories shows a statistically significant difference in progression-free and overall survivals.
regimen found that SUV max predicts for progression-free survival. OS was predicted by tumor stage, a finding that is expected. When analyzing SUV cutoffs for significance, a range of SUV values showed significant results for different endpoints. A meta-analysis of surgical studies utilizing differing SUV cutoffs by Paesmans et al also found that SUV max is a significant prognosticator for overall survival [3] . To date, similar studies on patients treated with either conventionally fractionated radiation therapy or SBRT have been unable to come to consensus on the utility of SUV max as a prognosticator [6] [7] [8] [9] [10] 15, 21] . Ikushima et al's study of definitive external beam radiation found SUV max to be related to tumor size/stage but not outcomes and hypothesized that the result was due to partial volume effect (PVE) as outlined by Soret et al [21, 22] . In this study, we also found SUV max to be related to tumor size (p = .013), but tumor size did not predict for the same outcomes as SUV max . The results from Ikushima et al's study are in contrast to the results from the Sasaki group, which showed an SUV cutoff of 5 to be significant for OS and PFS in patients treated with conventional RT [15] . In the two studies which investigated SUV max as a prognostic factor for the treatment of early-stage NSCLC with SBRT and failed to achieve significance, both cite sample size as a possible contributor to the lack of findings [9, 10] . The studies that did find significance in SUV max as a predictor of outcomes also suffer from problems such as heterogeneous treatment dosing, tumor staging and location, and sample size [6] [7] [8] . With a reduction in confounding variables by evaluating patients with a uniformity in stage, treatment dose and fractionation, and confirmation that all patients do indeed have non-small cell lung cancer, this study is able to provide a more focused insight into the prognostic value of SUV max . An additional study by Abelson et al. infers that the amount of metabolically active tumor may be equally important to outcomes as the peak metabolic activity of the tumor and warrants further investigation to elucidate the relationship between the two [23] .
To better determine the external validity of the results of this study, the most appropriate SUV max cutoff needs to be generated from pooled data from multiple highvolume centers. To determine the applicability of this information to the general stage 1 SBRT lung population, this data needs to include patients without pathological confirmation of disease as well as those who were treated under alternative fractionation schedules. Additionally, studies that include medically operable patients will provide longer-term data than current studies which rely on inoperable patients, most of whom succumb to intercurrent disease. At the time of analysis in this study, the cause of death in at least 56% of the patients who had perished was attributable to intercurrent disease. Armed with the upfront knowledge that some patients have more aggressive disease than others, as well as the emerging evidence that early post-treatment FDG-PET scanning may allow further differentiation of at-risk patients [6] , clinical trials may emerge to offer treatment-intensification. There are several limitations to this study including size, limited follow-up, its retrospective nature, and the inherent variability of FDG-PET scans and SUV max measurements from machine to machine and interobserver variability. A multi-institutional prospective study which utilizes a standardized protocol for administering and reading FDG-PET scans as well as biopsy information to correlate tumor biology to scan information and outcomes is likely necessary to confirm the findings found herein.
SUV max appears to be a useful prognosticator for progression-free survival and overall survival in the therapy of early-stage NSCLC treated with SBRT. As a predictor in both dichotomous and continuous forms, SUV max seems to be correlated with the propensity of tumors to metastasize. Larger studies may reveal a more appropriate cutoff value for identifying patients with more aggressive disease, which may then provide the basis for clinical trials to identify the benefit of more vigorous therapy.
